Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.64 USD | +7.83% | +9.09% | -6.65% |
Jun. 12 | Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025 | MT |
Jun. 12 | Ultragenyx Pharmaceutical Launches Equity Offering | MT |
Business Summary
Number of employees: 1,276
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Crysvita Royalty
42.1
%
| 22 | 6.0 % | 183 | 42.1 % | +742.02% |
Crysvita
17.4
%
| 43 | 11.7 % | 76 | 17.4 % | +77.37% |
Dojolvi
16.3
%
| 56 | 15.3 % | 71 | 16.3 % | +27.01% |
Collaboration and License - Crysvita Collaboration Revenue in Profit-share Territory
16.1
%
| 215 | 59.2 % | 70 | 16.1 % | -67.58% |
Mepsevii
7.0
%
| 21 | 5.7 % | 30 | 7.0 % | +47.51% |
Evkeeza
0.8
%
| - | - | 4 | 0.8 % | - |
Collaboration and License - Daiichi Sankyo
0.3
%
| 8 | 2.1 % | 1 | 0.3 % | -80.76% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
North America
70.7
%
| 281 | 77.4 % | 307 | 70.7 % | +9.27% |
Latin America
17.8
%
| 45 | 12.3 % | 77 | 17.8 % | +72.98% |
Europe
10.9
%
| 36 | 10.0 % | 48 | 10.9 % | +30.70% |
Japan
0.5
%
| 1 | 0.3 % | 2 | 0.5 % | +91.56% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 23-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-31 |
Dennis Huang
CTO | Chief Tech/Sci/R&D Officer | 59 | 15-04-30 |
Samuel Wadsworth
CTO | Chief Tech/Sci/R&D Officer | 75 | 17-10-31 |
Joshua Higa
IRC | Investor Relations Contact | - | - |
Ernie Meyer
HRO | Human Resources Officer | 60 | 20-08-31 |
Karah Parschauer
LAW | General Counsel | 46 | 16-06-19 |
Vimal Srivastava
PRN | Corporate Officer/Principal | 58 | 11-07-31 |
Erik Harris
PRN | Corporate Officer/Principal | 54 | 16-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 17-04-05 |
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Daniel Welch
CHM | Chairman | 66 | 15-04-07 |
Matthew Fust
BRD | Director/Board Member | 59 | 13-12-31 |
Michael Narachi
BRD | Director/Board Member | 64 | 15-02-19 |
Corazon Sanders
BRD | Director/Board Member | 67 | 21-06-28 |
Shehnaaz Suliman
BRD | Director/Board Member | 52 | 19-01-29 |
Amrit Ray
BRD | Director/Board Member | 51 | 22-04-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 83,196,916 | 79,491,209 ( 95.55 %) | 63,575 ( 0.0764 %) | 95.55 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.65% | 3.44B | |
+16.93% | 124B | |
+17.01% | 109B | |
-7.23% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.79% | 16.61B | |
-37.63% | 16.43B | |
+2.17% | 13.4B | |
+24.42% | 11.47B |
- Stock Market
- Equities
- RARE Stock
- Company Ultragenyx Pharmaceutical Inc.